Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection

Area of Science:

• Hepatology
• Virology
• Pharmacology

Background:

• Hepatitis C virus (HCV) is a primary cause of cirrhosis and hepatocellular carcinoma (HCC).
• Eradicating HCV can potentially reduce HCC incidence in infected individuals.
• Early HCV therapies like protease inhibitors showed efficacy but had severe side effects.

Purpose of the Study:

• To review the evolution of HCV treatment strategies.
• To assess the efficacy and adverse events of direct-acting antiviral agents (DAAs).
• To identify the need for improved therapies in difficult-to-treat HCV patients.

Main Methods:

• Review of clinical data on first and second-generation HCV direct-acting antiviral agents (DAAs).
• Analysis of treatment regimens including protease inhibitors, peginterferon, ribavirin, and sofosbuvir.
• Evaluation of sustained virological response (SVR) rates and adverse events.

Main Results:

• First-generation protease inhibitors (telaprevir, boceprevir) improved SVR but caused severe adverse events.
• Second-generation DAAs (simeprevir, sofosbuvir) achieved higher SVR rates with comparable adverse events.
• Specific DAA regimens demonstrated high SVR for HCV genotypes 1 and 2.

Conclusions:

• HCV treatment has advanced significantly with DAAs, improving SVR rates.
• Current DAA therapies offer better efficacy, though adverse events remain a consideration.
• Further research is necessary to develop optimal treatments for difficult-to-treat HCV populations.